SCHEMBL2276227

SCHEMBL2276227

C[C@H](C(=O)O)N(C(=O)OC(C)(C)C)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MT-CO2 P00403 1/20 0.45
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
CYP3A4 P08684 4/20 0.37
CYP1A2 P05177 3/20 0.37
MAPT P10636 3/20 0.37
CYP2C19 P33261 3/20 0.37
PPARA Q07869 3/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C9 P11712 2/20 0.37
MAPK1 P28482 2/20 0.37
ATM Q13315 2/20 0.37
NFKB1 P19838 1/20 0.37
PPARG P37231 2/20 0.36
LMNA P02545 2/20 0.36
PMP22 Q01453 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4648001 1.00 MT-CO2 (0.45) MT-CO2MEN1KMT2ACHRNB2CHRNB4
SCHEMBL8364820 1.00 MT-CO2 (0.45) MT-CO2MEN1KMT2ACHRNB2CHRNB4
SCHEMBL642839 0.86 SMN1; SMN2 (0.41) MEN1KMT2ACHRNB2CHRNB4CHRNA3
SCHEMBL9382586 0.86 SMN1; SMN2 (0.41) MEN1KMT2ACHRNB2CHRNB4CHRNA3
SCHEMBL7479440 0.86 MT-CO2 (0.46) MT-CO2MEN1KMT2ACHRNB2CHRNB4
SCHEMBL7479568 0.86 MT-CO2 (0.46) MT-CO2MEN1KMT2ACHRNB2CHRNB4
SCHEMBL1208677 0.85 SMN1; SMN2 (0.37) MEN1KMT2ACYP2C19CYP2D6CYP2C9
SCHEMBL10521312 0.85 NR1H2 (0.34) MT-CO2CYP3A4MAPK1LMNAHTT
SCHEMBL5846260 0.85 KMT2A (0.40) MEN1KMT2ALMNAHTTNPSR1
SCHEMBL6832851 0.85 USP30 (0.32) MT-CO2LMNAHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989634-B2 Melanocortin receptor agonists LG LIFE SCIENCES LTD. (KR) 2011-08-02 US disclosed
EP-1685102-A4 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD (KR) 2008-08-20 EP disclosed
US-20070129346-A1 Melanocortin receptor agonists LG LIFE SCIENCES LTD. (KR) 2007-06-07 US disclosed
EP-1685102-A1 MELANOCORTIN RECEPTOR AGONISTS LG Life Sciences Ltd. (KR) 2006-08-02 EP disclosed
WO-2005047251-A1 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD. (KR) 2005-05-26 WO disclosed
WO-2005047253-A1 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD. (KR) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129346-A1 Melanocortin receptor agonists MC1R, MC3R, MC5R MT-CO2 1583/4885MEN1 632/4885KMT2A 1824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.